NAV

Luseogliflozin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Luseogliflozin is an SGLT2 inhibitor used to manage type 2 diabetes mellitus.

Generic Name
Luseogliflozin
DrugBank Accession Number
DB12214
Background

Luseogliflozin has been used in trials studying the treatment of Diabetes Melltius, Type 2.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 434.55
Monoisotopic: 434.17630986
Chemical Formula
C23H30O6S
Synonyms
  • Luseogliflozin
External IDs
  • TS 071
  • TS-071
  • TS-71
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofType 2 diabetes mellitus•••••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcarboseLuseogliflozin may increase the hypoglycemic activities of Acarbose.
AcebutololThe therapeutic efficacy of Luseogliflozin can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Luseogliflozin can be increased when used in combination with Acetazolamide.
AcetohexamideLuseogliflozin may increase the hypoglycemic activities of Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Luseogliflozin can be increased when used in combination with Acetyl sulfisoxazole.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
A10BK07 — Luseogliflozin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Anisoles / Toluenes / Alkyl aryl ethers / Thianes / Secondary alcohols / Polyols / Dialkylthioethers / Primary alcohols
show 1 more
Substituents
Alcohol / Alkyl aryl ether / Anisole / Aromatic heteromonocyclic compound / Dialkylthioether / Diphenylmethane / Ether / Hydrocarbon derivative / Methoxybenzene / Organic oxygen compound
show 10 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
C596HWF74Z
CAS number
898537-18-3
InChI Key
WHSOLWOTCHFFBK-ZQGJOIPISA-N
InChI
InChI=1S/C23H30O6S/c1-4-29-16-7-5-14(6-8-16)10-15-11-17(18(28-3)9-13(15)2)23-22(27)21(26)20(25)19(12-24)30-23/h5-9,11,19-27H,4,10,12H2,1-3H3/t19-,20-,21+,22-,23+/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-{5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl}-6-(hydroxymethyl)thiane-3,4,5-triol
SMILES
CCOC1=CC=C(CC2=CC([C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=C(OC)C=C2C)C=C1

References

General References
  1. FDA Thailand Product Information: Lusefi (luseogliflozin) oral tablets [Link]
  2. NPRA Product Information: Lusefi (luseogliflozin) oral tablets [Link]
PubChem Compound
11988953
PubChem Substance
347828495
ChemSpider
10161420
BindingDB
50315426
ChEBI
134725
ChEMBL
CHEMBL1093423
ZINC
ZINC000049087932
Wikipedia
Luseogliflozin

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, film coatedOral
Tablet, coatedOral2.5 mg
Tablet, coatedOral5 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0513 mg/mLALOGPS
logP2.57ALOGPS
logP2.28Chemaxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.85Chemaxon
pKa (Strongest Basic)-2.8Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area99.38 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity117.91 m3·mol-1Chemaxon
Polarizability47.57 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0011900000-f979e02e2434fc8bc3a8
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0122900000-13b3d91967cd76a3537e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kr-0744900000-b1d166dad0a3cd98733b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-05aa-4439400000-22a2a61323a728b315f5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00n0-2953200000-0e4ce4071cd97ac53360
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00aa-1193100000-434f3586156241081e9e
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-210.9382293
predicted
DarkChem Lite v0.1.0
[M-H]-199.77498
predicted
DeepCCS 1.0 (2019)
[M+H]+210.0431293
predicted
DarkChem Lite v0.1.0
[M+H]+201.88551
predicted
DeepCCS 1.0 (2019)
[M+Na]+210.6990293
predicted
DarkChem Lite v0.1.0
[M+Na]+207.79803
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:37 / Updated at May 21, 2021 10:22